Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Dermatol Ther. 2021 Mar;34(2):e14825. doi: 10.1111/dth.14825. Epub 2021 Feb 16.
Erythrodermic psoriasis (EP), which accounts for 1 to 2.25% of all psoriatic cases, typically occurs in patients with poor control of existing psoriasis. Secukinumab yields rapid and sustained improvements of signs and symptoms in patients with plaque psoriasis. Currently, clinical data on the treatment of EP with secukinumab are scarce. We describe two adult patients with severe EP, including one male and one female who were both ineligible for or resistant to acitretin or methotrexate treatment and had additional diseases. The patients underwent treatment with secukinumab using the standard regimen. After 4 weeks of treatment, a 75% reduction in the Psoriasis Area and Severity Index score (PASI 75) was achieved in both patients. Secukinumab was well tolerated and was continued for at least 32 weeks of treatment. We report the clinical use of secukinumab in the treatment of EP and review its potential role in the management of this severe condition.
红皮病型银屑病（erythrodermic psoriasis，EP）约占所有银屑病病例的 1%至 2.25%，通常发生在现有银屑病控制不佳的患者中。司库奇尤单抗可迅速并持续改善斑块状银屑病患者的体征和症状。目前，关于司库奇尤单抗治疗 EP 的临床数据较少。我们描述了两名患有严重 EP 的成年患者，其中一名男性和一名女性均不适合使用阿维 A 或甲氨蝶呤治疗或对此类药物耐药，且还患有其他疾病。患者采用标准方案接受司库奇尤单抗治疗。治疗 4 周后，两名患者的银屑病面积和严重程度指数（PASI）评分均下降了 75%（PASI 75）。司库奇尤单抗的耐受性良好，至少继续治疗了 32 周。我们报告了司库奇尤单抗在 EP 治疗中的临床应用，并回顾了其在这种严重疾病管理中的潜在作用。
